Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?
The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.
You may also be interested in...
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.
New studies show Regeneron and Lilly’s leading COVID-19 antibody cocktails are ‘inactive’ against Omicron but there is better news for Vir, AstraZeneca and Adagio.